Thomas Chapman is chief of development and quality at Alcala Pharmaceuticals. The clinical lab specializes in analyzing urine samples for patient drug compliance as well as performing genetic testing by Next Generation Sequencing for personalized pain management. He is an expert in analysis of natural and exogenous compounds in human matrices and pharmaceuticals.
Chapman was previously a manager at Allergan in Irvine, CA, where he was responsible for the release of raw materials used to manufacture clinical trial material. In addition, he was responsible for the validation of raw material, medical device and finished product methods and FDA submissions. He is past chair of the USP Residual Solvents team and faculty member of the USP.
He received his Ph.D. in pediatrics endocrinology and analytic chemistry from the University of Groningen and has been an Extension instructor since 2003.